Company Snapshot: MKG  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Mallinckrodt Improves its Oxygen Therapy Line With New Aeris(TM) 590 Oxygen Concentrator

    ST. LOUIS, Oct. 25 /PRNewswire/ -- The new Puritan Bennett(R) Aeris(TM)
590 oxygen concentrator from Mallinckrodt Inc. (NYSE: MKG) is another of the
healthcare company's growing line of products designed for patients suffering
from chronic obstructive pulmonary disease.  The Aeris 590 provides
supplemental oxygen primarily to patients in a home setting, but it can also
be used in subacute settings such as nursing homes.
    The Aeris 590 is lighter, quieter and easier to move and handle than its
popular predecessor, the Puritan Bennett Companion(R) 590.  Other improvements
to the Aeris 590 include:

    -- a modular sieve bed design that integrates connectors and
       fittings in a manifold for easy maintenance and reduced failures due to
       leaks.
    -- a newly designed valve system, which replaces the diaphragm design, for
       increased reliability and serviceability.  If repairs are needed,
       getting inside the unit is as simple as removing two screws.

    "Customers were asking for these changes, and we responded," said Gerald
R. Mattys, vice president, general manager of Mallinckrodt's Alternate Care
business.  "The Aeris 590 is modeled on the best, the Companion 590, and we
have made the best even better.  For all its advantages, the Aeris 590 is also
surprisingly affordable."
    Other features of the new Aeris 590 include:

    -- a superior directed air flow cooling system that extends
       compressor life and improves performance
    -- a four-stage filtration system to reduce contamination
    -- superior oxygen concentration at all liter flows

    Based in St. Louis, Missouri, Mallinckrodt Inc. is a global manufacturer
and marketer of specialty medical products designed to sustain breathing,
diagnose disease, and relieve pain.  The company does business in
more than 100 countries, operates Respiratory, Imaging and Pharmaceuticals
product groups and had fiscal 1999 net sales of $2.6 billion.  The
Mallinckrodt website address is http://www.mallinckrodt.com.
    Contact:  Media, Barbara Abbett, 314-654-5230 or e-mail,
barbara.abbett@mkg.com, investors, Barbara Gould, 314-654-3190, or
e-mail, Invest@mkg.com, or customers, Customer Service Department,
800-635-5267, Ext. 2, all of Mallinckrodt Inc.


SOURCE Mallinckrodt Inc.




Back to Topback to top

Related links:
  • http://www.mallinckrodt.com
    Company News On-Call:
  • http://www.prnewswire.com/comp/440950.html or fax,
    800-758-5804, ext. 440950
    Contact: Media, Barbara Abbett, 314-654-5230 or e-mail,
    barbara.abbett@mkg.com, investors, Barbara Gould, 314-654-3190,
    or e-mail, Invest@mkg.com, or customers, Customer Service
    Department, 800-635-5267, Ext. 2, all of Mallinckrodt Inc.